Gain-of-function MiRNA Signature by Mutant P53 Associates with Poor Cancer Outcome

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Feb 4

PMID 26840456

Citations 20

Authors

Yao Zhang

Ye Hu

Jing-Yuan Fang

Jie Xu

Affiliations

Soon will be listed here.

Abstract

Missense mutation of p53 not only impairs its tumor suppression function, but also causes oncogenic gain of function (GOF). The molecular underpinning of mutant p53 (mutp53) GOF is not fully understood, especially for the potential roles of non-coding genes. Here we identify the microRNA expression profile (microRNAome) of mutp53 on Arg282 by controlled microarray experiments, and clarify the prognostic significance of mutp53-regulated miRNAs in cancers. A predominant repression effect on miRNA expression was found for mutant p53, with 183 significantly downregulated and only 12 upregulated miRNAs. Mutp53 and wild-type (wtp53) commonly upregulate let-7i, and other two miRNAs were upregulated by wtp53 but repressed by mutp53 (miR-610 and miR-3065-3p). Based the mutp53-regulated miRNA signature, a non-negative matrix factorization (NMF) model classified gastric cancer (GC) cases into subgroups with significantly different Disease-free survival (Kaplan-Meier test, P = 0.013). In contrast, the NMF model based on all miRNAs did not associate with cancer outcome. The mutp53 miRNA signature associated with the outcomes of breast cancer (P = 0.024) and hepatocellular cancer (P = 0.012). The miRPath analysis revealed that mutp53-suppressed miRNAs associate with Hippo, TGF-β and stem cell signaling pathways. Taken together, our results highlight a miRNA-mediated GOF mechanism of mutant p53 on Arg282, and suggest the prognostic potential of mutp53-associated miRNA signature.

Citing Articles

Deregulation mechanisms and therapeutic opportunities of p53-responsive microRNAs in diffuse large B-cell lymphoma.

Voropaeva E, Orlov Y, Loginova A, Seregina O, Maksimov V, Pospelova T PeerJ. 2025; 13():e18661.

PMID: 39802185 PMC: 11720970. DOI: 10.7717/peerj.18661.

Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma.

Tai M, Bantis L, Parhy G, Kato T, Tanaka I, Chow C Int J Mol Sci. 2024; 25(4).

PMID: 38397007 PMC: 10888571. DOI: 10.3390/ijms25042331.

Mutant p53 Gain-of-Function Induces Migration and Invasion through Overexpression of miR-182-5p in Cancer Cells.

Madrigal T, Ortega-Bernal D, Herrera L, Gonzalez-De la Rosa C, Dominguez-Gomez G, Arechaga-Ocampo E Cells. 2023; 12(20).

PMID: 37887350 PMC: 10605582. DOI: 10.3390/cells12202506.

Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.

Yu S, Yang Y, Yang H, Peng L, Wu Z, Sun L Sci Rep. 2023; 13(1):7560.

PMID: 37161008 PMC: 10170086. DOI: 10.1038/s41598-023-34519-8.

Identification of three metabolic subtypes in gastric cancer and the construction of a metabolic pathway-based risk model that predicts the overall survival of GC patients.

Chen T, Zhao L, Chen J, Jin G, Huang Q, Zhu M Front Genet. 2023; 14:1094838.

PMID: 36845398 PMC: 9950121. DOI: 10.3389/fgene.2023.1094838.

References

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View

Ferreira-Teixeira M, Parada B, Rodrigues-Santos P, Alves V, Ramalho J, Caramelo F . Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. Oncotarget. 2015; 6(34):36185-201. PMC: 4742170. DOI: 10.18632/oncotarget.5517. View

Krell J, Frampton A, Colombo T, Gall T, de Giorgio A, Harding V . The p53 miRNA interactome and its potential role in the cancer clinic. Epigenomics. 2013; 5(4):417-28. DOI: 10.2217/epi.13.41. View

Buffa F, Camps C, Winchester L, Snell C, Gee H, Sheldon H . microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011; 71(17):5635-45. DOI: 10.1158/0008-5472.CAN-11-0489. View

Hermeking H . MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012; 12(9):613-26. DOI: 10.1038/nrc3318. View

Jain N, Thatte J, Braciale T, Ley K, OConnell M, Lee J . Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics. 2003; 19(15):1945-51. DOI: 10.1093/bioinformatics/btg264. View

Wang H, Liang L, Fang J, Xu J . Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers. Oncogene. 2015; 35(16):2011-9. DOI: 10.1038/onc.2015.304. View

Xu J, Reumers J, Couceiro J, De Smet F, Gallardo R, Rudyak S . Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol. 2011; 7(5):285-95. DOI: 10.1038/nchembio.546. View

Mullen A . Hippo tips the TGF-β scale in favor of pluripotency. Cell Stem Cell. 2014; 14(1):6-8. PMC: 3941189. DOI: 10.1016/j.stem.2013.12.009. View

10.

Saito A, Nagase T . Hippo and TGF-β interplay in the lung field. Am J Physiol Lung Cell Mol Physiol. 2015; 309(8):L756-67. DOI: 10.1152/ajplung.00238.2015. View

11.

Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y . Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep. 2014; 4:6088. PMC: 4133709. DOI: 10.1038/srep06088. View

12.

Zhao H, Shen J, Medico L, Wang D, Ambrosone C, Liu S . A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One. 2010; 5(10):e13735. PMC: 2966402. DOI: 10.1371/journal.pone.0013735. View

13.

Ahmed K, Chinnaiyan P, Fulp W, Eschrich S, Torres-Roca J, Caudell J . The radiosensitivity index predicts for overall survival in glioblastoma. Oncotarget. 2015; 6(33):34414-22. PMC: 4741462. DOI: 10.18632/oncotarget.5437. View

14.

Hu Y, Tian H, Xu J, Fang J . Roles of competing endogenous RNAs in gastric cancer. Brief Funct Genomics. 2015; 15(3):266-73. DOI: 10.1093/bfgp/elv036. View

15.

Calhoun S, Daggett V . Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain. Biochemistry. 2011; 50(23):5345-53. PMC: 3117291. DOI: 10.1021/bi200192j. View

16.

Hunten S, Kaller M, Drepper F, Oeljeklaus S, Bonfert T, Erhard F . p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses. Mol Cell Proteomics. 2015; 14(10):2609-29. PMC: 4597140. DOI: 10.1074/mcp.M115.050237. View

17.

Shi L, Reid L, Jones W, Shippy R, Warrington J, Baker S . The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006; 24(9):1151-61. PMC: 3272078. DOI: 10.1038/nbt1239. View

18.

Hu Y, Wang J, Qian J, Kong X, Tang J, Wang Y . Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. Cancer Res. 2014; 74(23):6890-902. DOI: 10.1158/0008-5472.CAN-14-0686. View

19.

Shi L, Jones W, Jensen R, Harris S, Perkins R, Goodsaid F . The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics. 2008; 9 Suppl 9:S10. PMC: 2537561. DOI: 10.1186/1471-2105-9-S9-S10. View

20.

Murray B, Choe S, Woods M, Ryan T, Liu W . An in silico analysis of microRNAs: mining the miRNAome. Mol Biosyst. 2010; 6(10):1853-62. DOI: 10.1039/c003961f. View